CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Idarubicin +3 moredrug
Likely dose
Idarubicin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02937662
NCT02937662Phase 2Completed
CompareCT.gov

Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML

Institute of Hematology & Blood Diseases Hospital, China·interventional·Posted Oct 18, 2016·Updated May 30, 2025

In Brief

A Phase 2 clinical trial evaluating Idarubicin, Cytarabine, and 2 other interventions for Acute Myeloid Leukemia. Completed, enrolled 20 participants across 1 site.

Detailed Summary

In this multi-center, randomized, open-label, prospective clinical trial, a total of 60 relapsed/refractory AML patients will be randomized into 2 groups. In the experimental arm, patients receive IAC regimen. In the control arm, patients receive other physician-directed regimen. The primary end point is complete remission rate.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 18, 2016
Enrollment StartOct 1, 2016
Primary CompletionApr 30, 2020
TodayJul 1, 2026
Enrollment to primary: 3.6 yearsPosted 9.7 years ago

Interventions

Idarubicindrug

Idarubicin at a dose of 10 mg/㎡/d on days 1-3.

Cytarabinedrug

Cytarabine at a dose of 100mg/㎡/d on days 1-7.

Cyclophosphamidedrug

Cyclophosphamide at a dose of 350mg/㎡/d on the second day and the fifth day.

Physician-Directed Regimens without Cyclophosphamidedrug

Regimen without cyclophosphamide including FLA±G regimen, DA regimen, AAG regimen, decitabine with AA regimen.